Editas Medicine Inc’s recent filing unveils that its EVP, CHIEF FINANCIAL OFFICER Lucera Erick unloaded Company’s shares for reported $7030.0 on Mar 04 ’25. In the deal valued at $1.71 per share,4,109 shares were sold. As a result of this transaction, Lucera Erick now holds 112,720 shares worth roughly $0.17 million.
Then, O’Neill Gilmore Neil sold 16,632 shares, generating $28,452 in total proceeds. Upon selling the shares at $1.71, the CEO now owns 295,474 shares.
Before that, Burkly Linda sold 2,891 shares. Editas Medicine Inc shares valued at $4,946 were divested by the EVP, CHIEF SCIENTIFIC OFFICER at a price of $1.71 per share. As a result of the transaction, Burkly Linda now holds 70,245 shares, worth roughly $0.1 million.
H.C. Wainwright initiated its Editas Medicine Inc [EDIT] rating to a Buy in a research note published on April 28, 2025; the price target was $3. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid December from “a Neutral” to “an Underweight”. Truist also remained covering EDIT and has decreased its forecast on December 13, 2024 with a “Hold” recommendation from previously “Buy” rating. Stifel revised its rating on December 13, 2024. It rated EDIT as “a Hold” which previously was an “a Buy”.
Price Performance Review of EDIT
On Monday, Editas Medicine Inc [NASDAQ:EDIT] saw its stock fall -1.32% to $1.49. Over the last five days, the stock has lost -3.25%. Editas Medicine Inc shares have risen nearly 17.32% since the year began. Nevertheless, the stocks have fallen -75.17% over the past one year.
How much short interest is there in Editas Medicine Inc?
A steep rise in short interest was recorded in Editas Medicine Inc stocks on 2025-04-30, dropping by -1.07 million shares to a total of 11.61 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 12.68 million shares. There was a decline of -9.26%, which implies that there is a negative sentiment for the stock.
